STOCKHOLM (Reuters) - Gene testing is shaping up to be a marketing battleground for new blood thinners like AstraZeneca's Brilinta, underscoring the power and limitations of genetics as a tool to ...
In a follow up investigation into the multibillion dollar drug ticagrelor, The BMJ has uncovered fresh concerns, this time in key platelet studies used in its FDA approval. For more than a decade, ...
The German Institute for Quality and Efficiency in Health Care (IQWiG) assessed the added benefit of ticagrelor for patients with acute coronary syndrome already in 2011 in its very first dossier ...
A drug developed as an antidote to the antiplatelet agent ticagrelor safely and effectively reversed ticagrelor's antiplatelet effects in patients undergoing urgent surgery or experiencing major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results